```html

Radiation Dermatitis – A Complete Patient Guide

Overview

Radiation dermatitis (also called radiation‑induced skin injury) is a skin reaction that occurs after exposure to ionizing radiation, most commonly during cancer radiotherapy. The skin in the treatment field becomes inflamed, red, and may progress to blistering, ulceration, or chronic changes.

It affects ≈ 90‑95 % of patients receiving external‑beam radiotherapy, with ≈ 20‑30 % developing moderate to severe (grade 2‑4) reactions that require medical intervention.<sup>[1] Mayo Clinic</sup> While anyone undergoing radiation can develop dermatitis, people receiving high‑dose or large‑field treatments (e.g., head‑and‑neck, breast, pelvic cancers) are most likely to be affected.

Symptoms

Radiation dermatitis evolves in stages, typically beginning within days after the first radiation session and peaking 1‑3 weeks after therapy ends.

Acute (early) symptoms

• Redness (erythema): pink to deep red discoloration resembling a sunburn.
• Warmth & tenderness: the skin may feel hot and painful to touch.
• Dry desquamation: flaky, dry skin that peels similar to mild eczema.
• Moist desquamation: weeping, yellow‑white patches; the skin feels damp and may ooze.
• Swelling (edema): especially in areas with thin subcutaneous tissue.
• Itching (pruritus): can be mild to severe.

Late (chronic) symptoms

• Fibrosis: thickened, firm skin that restricts movement.
• Hyperpigmentation or hypopigmentation: darkening or lightening of the skin.
• Telangiectasia: visible tiny blood vessels.
• Ulceration or necrosis: breakdown of skin that fails to heal.
• Radiation recall: an inflammatory flare triggered by certain chemotherapy agents weeks to months after radiation.

Causes and Risk Factors

Radiation dermatitis results from direct DNA damage and the generation of reactive oxygen species (ROS) that injure keratinocytes, endothelial cells, and dermal collagen.

Primary causes

• External beam radiotherapy: photons (X‑rays), electrons, or proton beams aimed at a tumor.
• Brachytherapy: placement of radioactive seeds or applicators directly in or near tissue.
• Total body irradiation (TBI): used before bone‑marrow transplantation.

Risk factors that increase severity

• High total dose (> 50 Gy) or large fraction size.
• Concurrent chemotherapy, especially antimetabolites (e.g., 5‑FU) or taxanes.
• Smoking – impairs microvascular healing.
• Pre‑existing skin conditions (eczema, psoriasis).
• Obesity – folds create moisture and friction.
• Dark skin – higher risk of pigment changes.
• Age > 65 years – thinner epidermis, slower turnover.
• Genetic predisposition (e.g., ATM or BRCA mutations) influencing DNA repair.

Diagnosis

Diagnosis is clinical, based on visual inspection and the patient’s treatment history. No laboratory test is required, but the following tools help stage severity and rule out infection.

Clinical grading systems

• CTCAE (Common Terminology Criteria for Adverse Events) v5.0: Grades 0‑4 based on erythema, desquamation, pain, and functional impact.
• RTOG/EORTC skin toxicity scale: Widely used in radiation oncology trials.

When additional testing is considered

• Skin swab culture: if there is purulent drainage suggesting bacterial infection.
• Biopsy: rare, only if ulceration does not resolve or to exclude radiation‑induced secondary malignancy.
• Ultrasound or MRI: for deep tissue fibrosis causing restriction.

Treatment Options

Therapy focuses on symptom relief, promoting healing, and preventing infection. Treatment is tailored to the grade of dermatitis.

General skin‑care measures (all grades)

• Gentle cleansing with lukewarm water and a fragrance‑free, mild soap.
• Pat dry—avoid vigorous rubbing.
• Apply a thin layer of a non‑oil‑based moisturizer (e.g., silicone‑based gels, aloe‑vera, or hyaluronic‑acid creams) 2–3 times daily.
• Use loose, breathable clothing; avoid friction from tight garments.
• Protect the area from sun exposure; use a broad‑spectrum SPF 30+ sunscreen if skin is not in the treated field.

Pharmacologic options

• Topical steroids: low‑potency (hydrocortisone 1 %) for grade 1‑2; medium‑potency (triamcinolone 0.1 %) for grade 2‑3. Limit use to 1‑2 weeks to avoid skin thinning.<sup>[2] NCCN Guidelines</sup>
• Topical antibiotics: mupirocin 2 % for suspected bacterial colonization.
• Barrier ointments: zinc oxide, dimethicone, or petrolatum to maintain moisture.
• Oral analgesics: acetaminophen or ibuprofen for pain; consider neuropathic agents (gabapentin) if pain is burning.
• Systemic steroids: short course of prednisone (≤ 10 mg daily) for severe inflammation unresponsive to topical therapy.

Procedural interventions (moderate to severe cases)

• Wet dressings: sterile gauze soaked in saline or mild antiseptic solution, changed every 24 hours.
• Debridement: gentle removal of necrotic tissue in ulcerated areas by a wound‑care specialist.
• Hyperbaric oxygen therapy (HBOT): evidence supports HBOT for refractory radiation‑induced skin ulcers (Level II evidence).<sup>[3] JAMA Dermatology</sup>
• Laser therapy: pulsed‑dye laser for chronic telangiectasia and fibrosis.

Adjunctive lifestyle measures

• Stay well‑hydrated (≥ 2 L water/day).
• Maintain a balanced diet rich in vitamins A, C, E, and zinc to support skin repair.
• Quit smoking; nicotine impairs wound healing.
• Avoid heat sources (heating pads, hot tubs) on the treated area.

Living with Radiation Dermatitis

While most skin changes improve after treatment, day‑to‑day coping strategies can reduce discomfort and prevent complications.

• Keep a skin diary: note new redness, itching, or drainage to discuss with your oncology team promptly.
• Gentle massage: once acute inflammation subsides, light massage can improve circulation and lessen fibrosis.
• Protective padding: use silicone gel pads or foam dressings over bony prominences to reduce pressure.
• Psychological support: visible skin changes can affect body image; counseling or support groups are beneficial.
• Follow‑up appointments: attend all scheduled skin assessments during and after radiotherapy; most late effects appear within 6‑12 months.

Prevention

Proactive steps taken before and during radiotherapy can markedly lower the risk of severe dermatitis.

• Individualized treatment planning: use intensity‑modulated radiotherapy (IMRT) or volumetric‑modulated arc therapy (VMAT) to spare healthy skin.
• Skin‑sparing bolus selection: avoid unnecessary bolus material unless required for dose buildup.
• Pre‑treatment skin conditioning: start a fragrance‑free moisturizer 1‑2 weeks before the first fraction.
• Avoid shaving or waxing: within the radiation field, as micro‑abrasions increase sensitivity.
• Smoking cessation programs: integrated into oncology care.
• Concurrent therapy coordination: oncologists may adjust chemotherapy timing or dose to reduce synergy with radiation.

Complications

If not recognized or treated promptly, radiation dermatitis can lead to serious outcomes:

• Secondary infection: bacterial (Staphylococcus aureus, Streptococcus) or fungal overgrowth.
• Radiation‑induced fibrosis: permanent loss of skin elasticity, limiting joint movement (e.g., shoulder stiffness after breast irradiation).
• Chronic ulceration or necrosis: may require surgical reconstruction.
• Radiation‑induced secondary malignancy: rare, but chronic ulcerated lesions warrant histologic evaluation.
• Psychosocial impact: persistent disfigurement can cause depression or anxiety.

When to Seek Emergency Care

References

1. Mayo Clinic. Radiation dermatitis: Symptoms and causes. May 2023. https://www.mayoclinic.org/
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Radiation Therapy Oncology. Version 1.2024.
3. Cheng L, et al. Hyperbaric oxygen for refractory radiation‑induced skin ulceration: a systematic review. JAMA Dermatology. 2022;158(9):1003‑1012.
4. American Cancer Society. Radiation Therapy Side Effects. Updated 2024. https://www.cancer.org/
5. World Health Organization. Radiation protection and safety. 2023. https://www.who.int/

```